In the meta-analysis by Champs et al. on cytokine-neutralizing antibodies in psoriatic arthritis and psoriasis, anti-IL-17 treatment with secukinumab, ixekizumab, and brodalumab showed no significant short-term risks of major adverse cardiovascular events or congestive HF when compared to a placebo [93]. The gene discussed is IL17A; the disease is psoriasis.